Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy

X
Trial Profile

Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esonadogene imvoparvovec (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2022 According to a Neurophth Therapeutics media release, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for NR082 for the treatment of Leber's hereditary optic neuropathy (LHON) associated with mtND4 mutation, based on compelling IND-enabling data and clinical data of 186 subjects from three investigator-initiated trials (IITs).
    • 24 Sep 2020 According to a Neurophth Therapeutics media release,at the 23rd online annual meeting of the American Society for Gene and Cell Therapy (ASGCT) and the online annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Neurophth presented (in May 2020) the two clinical research data (NCT01267422 and NCT03153293) on the treatment of LHON with NR082 (NFS-01 project of rAAV2-ND4).
    • 24 Sep 2020 According to a Neurophth Therapeutics media release, longest follow-up record of gene therapy in the world from this study, has been published in the Scientific Report, EBioMedicine and Ophthalmology journals.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top